Does Empirical Therapy with a Fluoroquinolone or the Combination of a ?-Lactam Plus a Macrolide Result in Better Outcomes for Patients Admitted to the General Ward?

• Autores: Jörg Ruhe
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 27, Nº. 1, 2013 (Ejemplar dedicado a: Community-Acquired pneumonia: Controversies and questions), págs. 115-132
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Community-acquired pneumonia (CAP) is a frequent cause of morbidity and mortality in the United States and worldwide, in particular among older patients and those with significant comorbid conditions. Current guidelines recommend therapy with a fluoroquinolone or a ?-lactam plus a macrolide for the treatment of hospitalized adults with CAP who do not require admission to an intensive care unit. This article provides a brief summary and overview of the existing literature on this topic categorized by the main results; the potential implications for future clinical practice and research are discussed.